Form 4: Opko Health Sells GeneDx Holdings Corp. Shares in Multiple Transactions

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A Common Stock in a series of transactions.

Summary

• Opko Health, Inc., a major shareholder of GeneDx Holdings Corp., has reported the sale of Class A Common Stock.
• On July 19, 2024, Opko Health sold 25,000 shares at a price of $32.29 per share.
• On July 22, 2024, an additional 50,000 shares were sold at a weighted average price of $32.6088 per share, with individual transactions ranging from $32.00 to $33.02.
• On July 23, 2024, Opko Health sold 75,000 shares at a weighted average price of $33.4566 per share, with individual transactions ranging from $32.72 to $34.50.
• Following these transactions, Opko Health's direct ownership in GeneDx Holdings Corp. stands at 3,258,403 shares.

Sentiment

Score: 4

Explanation: The document indicates a major shareholder is selling shares, which could be interpreted negatively by the market, but it's a routine transaction. The sentiment is neutral to slightly negative.

Risks

• The market may react negatively to the news of a major shareholder selling off shares.

Industry Context

Sales of shares by significant shareholders are common and can be for various reasons, including portfolio rebalancing or raising capital for other ventures. The impact on GeneDx's stock price will depend on market perception and the overall health of the diagnostics industry.

Stakeholder Impact

• Shareholders may react to the news of Opko Health selling shares, potentially impacting the stock price.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal unless the share sale signals a larger strategic shift.

Key Dates